SENSEX NIFTY

Trastuzumab

Jan 12, 2017 at 09:44 | Source: Moneycontrol.com
Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
Jan 12, 2017 at 08:56 | Source: PTI
The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the two companies said in a statement.
Jan 12, 2017 at 08:43 | Source: CNBC-TV18
Following US president-elect Donald Trumps explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.
Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Dec 27, 2016 at 15:41 | Source: Moneycontrol.com
This study was the last major step of a multiple-phased programme to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.
Dec 22, 2016 at 12:02 | Source: CNBC-TV18
Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.
Dec 06, 2016 at 12:52 | Source: CNBC-TV18
Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.
Aug 26, 2016 at 09:13 | Source: CNBC-TV18
The European Medicines Agency (EMA) has accepted to review Mylan and Biocons application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.
Aug 25, 2016 at 20:46 | Source: PTI
This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe, global pharma major Mylan and Biocon said in a statement today.
Jun 04, 2016 at 15:30 | Source: PTI
Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, incomparison to Roche's branded Herceptin used for treatment of cancer
Messages on Trastuzumab »

BSE/NSE Announcer

Platinum Member

20352 Followers

Biocon  

Biocon Ltd has informed BSE regarding a Press Release dated January 11, 2017, titled "U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocons Proposed Biosimilar Trastuzumab".

6.32 PM Jan 11th

savera_patn
a

Platinum Member

40 Followers

Biocon  

Bond 007 !!! Glargine EU approval by end of 2017 is my estimated timeline , Peg-filgrastim July 2017 then Trastuzumab by December 17 ....

11.27 AM Jan 10th

dhruvfun

New Member

3 Followers

Biocon  

i can`t believe how people are not able to understand what biocon is !! biocon is a world class biopharma firm, that has world class talent pool of scientists!! its trastuzumab biosimilar is showing much better results than herceptin which generates 40,000 crores alone in revenue for roche!! it

10.07 AM Jan 5th

rjstocks99

New Member

0 Follower

Biocon  

Published study results showed an overall response rate of 69.6 per cent for MYL-1401O compared to 64 per cent for branded trastuzumab

5.41 PM Dec 28th 2016

rjstocks99

New Member

0 Follower

Biocon  

Hope S. Rugo, professor of medicine at the University of California, San Francisco, said: This study was the last major step of a multiple-phased program to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.

5.40 PM Dec 28th 2016

rjstocks99

New Member

0 Follower

Biocon  

The results confirm the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon, in comparison to branded trastuzumab, according to a company statement

5.33 PM Dec 28th 2016

biomagic

New Member

14 Followers

Biocon  

Know the outcome- We are encouraged by the confirmatory efficacy and safety results of the HERITAGE study recently published in JAMA. This study was the last major step of a multiple-phased program to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison

1.29 PM Dec 27th 2016

biomagic

New Member

14 Followers

Biocon  

Recovery starts post lunch... buy before it is out of reach. Launch of Proposed Biosimilar Trastuzumab is going to happen in no time in USA!!!

12.47 PM Dec 27th 2016

biomagic

New Member

14 Followers

Biocon  

Biocon Ltd has informed BSE regarding a Press Release dated December 27, 2016 titled "Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon``s Proposed Biosimilar Trastuzumab Phase 3 Data".

12.35 PM Dec 27th 2016

BSE/NSE Announcer

Platinum Member

20352 Followers

Biocon  

Biocon Limited has informed the Exchange regarding a press release dated December 27, 2016, titled "Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon s Proposed Biosimilar Trastuzumab Phase 3 Data".

12.22 PM Dec 27th 2016

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.